Protalex Announces Acceptance of Abstract Highlighting Findings from U.S. Phase 1(b) Trial of PRTX-100 in Active Rheumatoid Arthritis Patients at the 2014 American College of Rheumatology Annual Meeting
FLORHAM PARK, N.J.--(BUSINESS WIRE)--Protalex, Inc. (OTCQB:PRTX), a clinical-stage biopharmaceutical company, today announced that an abstract highlighting results from Cohorts 1-4 of its U.S.-based multicenter Phase 1(b) randomized, multiple-dose, dose-escalation study of PRTX-100 in combination with methotrexate or leflunomide in adults with active rheumatoid arthritis (PRTX-100-104 Study) was accepted for poster presentation at the upcoming American College of Rheumatology (ACR) and the Association for Rheumatology Health Professionals (ARHP) Annual Meeting 2014 being held in Boston, Massachusetts from November 14-19, 2014. The abstract will be available at the ACR’s website at http://www.acrannualmeeting.org and on the Company’s website at www.protalex.com.
“A Phase 1 Dose-Ranging Repeated-Dose Trial of Parenteral Staphylococcal Protein A (PRTX-100) in Patients with Active Rheumatoid Arthritis on Methotrexate or Leflunamide Therapy”
The poster will be available for viewing as follows:
"A Phase 1 Dose-Ranging Repeated-Dose Trial of Parenteral Staphylococcal Protein A (PRTX-100) in Patients with Active Rheumatoid Arthritis on Methotrexate or Leflunamide Therapy”
|Session Name:||Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy: Novel therapies, Biosimilars, Strategies and Mechanisms in Rheumatoid Arthritis|
|Poster Presentation Time:||November 17, 2014 from 8:30 a.m. – 4:00 p.m. (local time)|
|Location:||Exhibit Hall B|
About Protalex, Inc.
Protalex, Inc. is a clinical-stage biopharmaceutical company focused on the development of a class of drugs for treating autoimmune and inflammatory diseases including rheumatoid arthritis (RA). Protalex’s lead product, PRTX-100, is a formulation of a proprietary, highly purified form of Staphylococcal Protein A, which is an immunomodulatory protein produced by bacteria. PRTX-100 has the ability, at very low concentrations, to bind to human B-lymphocytes and macrophages and to modulate immune processes. The safety, tolerability, and pharmacokinetics of PRTX-100 have been characterized in five clinical studies. In a Phase 1b clinical trial in adult patients with active RA in South Africa PRTX-100 was generally safe and well tolerated at all dose levels, and at the higher doses, more patients showed improvement in their CDAI (Clinical Disease Activity Index) for RA than did patients at the lower dose or placebo cohorts.
Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause the Company's actual operating results to be materially different from any historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements that explicitly describe these risks and uncertainties, readers are urged to consider statements that contain terms such as "believes," "belief," "expects," "expect," "intends," "intend," "anticipate," "anticipates," "plans," "plan," to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's filings with Securities and Exchange Commission.